[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566948":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Beijing Boren Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T treatment","EXPERIMENTAL",null,[13],"Drug: CAR-T",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","CAR-T","CAR-T cells",[9],[21],{"name":22,"affiliation":23,"role":24},"Yajing Zhang, MD\u002FPhD","Beijing Gaobo Boren Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","+8601083605002（716）","z18501333856@126.com",[31],{"facility":23,"status":11,"city":32,"state":11,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Beijing","100070","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100566948",false,"NCT06661811","A Study of CAR-T Cells Targeting Autoimmune Diseases","A Study of CAR-T Cells Targeting B Cell Related Autoimmune Diseases","Inclusion Criteria:\n\n1. Male or female, between 18 and 56 years old;\n2. Diagnosed with Autoimmune Diseases；\n3. Good organ functions;\n4. Voluntary participates this trial and can comprehend and sign ICF.\n\nExclusion Criteria:\n\n1. Had or has active malignancy;\n2. Had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;\n3. Combined with other autoimmune disease that needs treatment;\n4. Pregnant or lactating women;\n5. Has other factors that deemed not suitable by investigator.","ALL","18 Years","65 Years",{"count":56,"type":57},12,"ESTIMATED","INTERVENTIONAL",[60],"NA","The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.",[63],"Autoimmune Diseases","NOT_YET_RECRUITING","2024-10-25",{"date":67,"type":68},"2024-10-28","ACTUAL",{"date":70,"type":57},"2024-11-15",{"date":72,"type":57},"2028-06-20",{"name":5,"class":6},1]